ID: ALA2286213

Max Phase: Preclinical

Molecular Formula: C14H11ClF2N4O3S2

Molecular Weight: 420.85

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nn(-c2cc3nc(SCCC(=O)O)sc3cc2Cl)c(=O)n1C(F)F

Standard InChI:  InChI=1S/C14H11ClF2N4O3S2/c1-6-19-21(14(24)20(6)12(16)17)9-5-8-10(4-7(9)15)26-13(18-8)25-3-2-11(22)23/h4-5,12H,2-3H2,1H3,(H,22,23)

Standard InChI Key:  WVJPWSNSDQZEIX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 420.85

Molecular Weight (Monoisotopic): 419.9929

AlogP: 3.57

#Rotatable Bonds: 6

Polar Surface Area: 90.01

Molecular Species: ACID

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.93

CX Basic pKa: 0.62

CX LogP: 4.14

CX LogD: 0.94

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.61

Np Likeness Score: -1.97

References

1. Zuo Y, Yang SG, Luo YP, Tan Y, Hao GF, Wu QY, Xi Z, Yang GF..  (2013)  Design and synthesis of 1-(benzothiazol-5-yl)-1H-1,2,4-triazol-5-ones as protoporphyrinogen oxidase inhibitors.,  21  (11): [PMID:23623257] [10.1016/j.bmc.2013.03.056]

Source

Source(1):

• Scientific Literature